This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The following model parameters were assessed within the review of the literature: the relative risk (RR) and age-specific population risks of CHD, VTE, stroke, breast cancer, colorectal cancer, hip fracture, vertebral fracture and other osteoporotic fracture; the age-specific annual mortality rates for the general population; and the age-specific mortality rates from hip fractures and clinical vertebral fractures.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately five primary studies were reviewed for the estimation of model parameters.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The following estimates used within the model were reported.
For women with an intact uterus on combination therapy, the RR was 1.29 for CHD, 1.41 for stroke, 2.11 for VTE, 1.26 for breast cancer, 0.63 for colorectal cancer, 0.66 for hip fracture and vertebral fracture, and 0.77 for osteoporotic fracture.
For women with a hysterectomy on oestrogen-only therapy, the RR was 0.91 for CHD, 1.39 for stroke, 1.33 for VTE, 0.77 for breast cancer, 1.08 for colorectal cancer, 0.61 for hip fracture, 0.62 for vertebral fracture, and 0.70 for osteoporotic fracture.
Details of other parameters used within the model were reported in a working paper (Zethraeus et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic details). The authors made some assumptions when literature-based estimates were not available.
Methods used to derive estimates of effectiveness

Estimates of effectiveness and key assumptions
The authors assumed that 30% of the observed excess mortality after a hip or vertebral fracture was associated with the fracture event. In addition, they assumed that the gain in quality of life due to HRT was equal to 0.29, which was equal to the average of a women with menopausal symptoms.
Measure of benefits used in the economic analysis
The summary measures of benefits were the life-years gained and the quality-adjusted life-years (QALYs) gained. Both of the measures were estimated through the use of a Markov model that determined the long-term effects of treatment with HRT.
Direct costs
The quantity/cost boundary adopted in the economic study was that of society. The costs included were those borne by the hospital, patients and society, such as initial and annual intervention costs (including drug costs and costs of hospital and physician visits), direct fracture costs, and the cost-savings and costs incurred because of changes in morbidity due to HRT treatment. The resource use and the unit costs were not presented separately. All costs were discounted at an annual rate of 3%. The price year was 2003.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
Indirect costs due to fracture were included in the economic study. The costs were discounted at an annual rate of 3%.
The price year was 2003.
Currency
Swedish kroner (SEK).
Sensitivity analysis
One-way sensitivity analyses and a threshold analysis were conducted to test the robustness of the results. The variables included the effects of HRT, remaining effects of HRT, size of the quality of life improvement, treatment duration, intervention cost, and the discount rates of costs and benefits.
Estimated benefits used in the economic analysis
The authors reported the life-years gained and QALYs gained for each of the six groups, compared with no treatment. The benefits were discounted at a rate of 3%.
For women with a hysterectomy on oestrogen-only therapy, HRT resulted in a gain from 0.006 to 0.03 in life-years and a gain from 1.2 to 1.3 in QALYs.
For women with an intact uterus on combination therapy, HRT resulted in a gain from 0.02 to 0.03 in life-years and a gain from 1.2 to 1.3 in QALYs.
Cost results
The costs with no HRT and with HRT for 50-year-old women with an intact uterus were SEK 804,024 and SEK 
Synthesis of costs and benefits
Compared with no therapy, the cost per QALY gained for women with an intact uterus were SEK 12,807 for 50-yearold women, SEK 10,844 for 55-year-old women and SEK 9,159 for 60-year-old women.
Compared with no therapy, the costs per QALY gained for women with a hysterectomy were SEK 8,266 for 50-yearold women, SEK 7,960 for 55-year-old women and 11,043 for 60-year-old women.
For women with both intact uterus and hysterectomy, the cost-effectiveness results were stable to all but one of the alternative scenarios. The results were sensitive to whether the therapy had a positive effect on menopausal symptoms or not.
The threshold analysis revealed that HRT was cost-effective for women with or without a hysterectomy if the gain in quality of life exceeded 0.013 units.
